# Biomarker analysis report

2017-08-29

#### Contents

| 1 | 1 The dataset   |                         | 1  |  |  |  |
|---|---|-------------------------|----|--|--|--|
| 2 | Representativeness: Selection Bias of Biomarker Population                              |                         |    |  |  |  |
|   | 2.1 Check selection bias in terms of key clinical variables, between full population as | $\operatorname{ad}$ BEP | 2  |  |  |  |
|   | 2.2 Check whether the clinical outcome in BEP is comparable to the full population      |                         | 2  |  |  |  |
|   | 2.3 Examine whether the prognostic/predictive/null trend of key clinical variables h    | olds in BEP .           | 3  |  |  |  |
| 3 | Biomarker property and its association to clinical variables                            |                         |    |  |  |  |
|   | 3.1 Biomarker property and relationship to clinical variable                            |                         | 6  |  |  |  |
|   | 3.2 Whether the biomarker shows within-arm effect                                       |                         |    |  |  |  |
| 4 | 4 Biomarker subgroup analysis   |                         | 8  |  |  |  |
|   | 4.1 Estimations within each subgroup  |                         | 8  |  |  |  |
|   | 4.2 Subgroup analysis   |                         | 9  |  |  |  |
|   | 4.3 Check whether biomarker subgroup is confounded with key clinical variables          |                         | 10 |  |  |  |

#### 1 The dataset

The dataset have 550 entries. In which 326 are in biomarker evaluable population (BEP).

Endpoint of interest: Lab\_ontrtBiomarker: KRAS.mutantBiomarker type: categorical

# 2 Representativeness: Selection Bias of Biomarker Population

In this section, we are trying to answer the question: Are biomarker evaluable population representative of the full population population?

Key baseline demographics and prognostic characteristics (including stratification variables and any variables with known prognostic effect) and efficacy outcomes should be summarized by treatment groups and compared between biomarker evaluable population (BEP) and the full population. These analyses are conducted to investigate any potential selection bias associated with the availability of the biomarker (e.g. we may not get enough tissue for patients whose tumor size is small. Therefore they may be excluded from BEP).

The key clinical biomarkers considered are:

clinical.vars.class


## Sex Age
## "categorical" "numeric"

# 2.1 Check selection bias in terms of key clinical variables, between full population and BEP

|              | All(CTRL)  | BEP(CTRL)   | All(TRT)  | BEP(TRT)     |
|--------------|------------|-------------|-----------|--------------|
| Sex          |            |             |           |              |
| Total        | 182        | 103         | 368       | 223          |
| NA's         | 0          | 0           | 0         | 0            |
| $\mathbf{F}$ | 89 (48.9%) | 47 (45.63%) | 184 (50%) | 111 (49.78%) |
| $\mathbf{M}$ | 93 (51.1%) | 56 (54.37%) | 184 (50%) | 112 (50.22%) |
| Age          | , ,        | ,           | , ,       | ,            |
| N            | 182        | 103         | 368       | 223          |
| Mean         | 52.54      | 52.93       | 54.03     | 54.27        |
| Median       | 51.5       | 52          | 54        | 54           |
| Min-Max      | 2785       | 3285        | 3089      | 3389         |
| NA's         | 0          | 0           | 0         | 0            |

# 2.2 Check whether the clinical outcome in BEP is comparable to the full population

The following plot compares continuous outcome in BEP vs. the full population. The response category distribution is plotted for each arm. The BEP bars are expected to be comparable to those in full population.



# 2.3 Examine whether the prognostic/predictive/null trend of key clinical variables holds in BEP

The following forest plot can be used to examine whether any of the key prognostic/predictive clinical variables still show prognostic/predictive trend in BEP:


# Across arm, Compare BEP vs. All Lab\_ontrt Unadjusted, unstratified analysis


| Subgroup           | Group | Mean  | delta | (CI)           | raw P   |  |
|--------------------|-------|-------|-------|----------------|---------|--|
| ITT Sex(F)         | CTRL  | 18.86 |       |                |         |  |
|                    | TRT   | 22.11 | 3.25  | (1.38 – 5.11)  | 0.00073 |  |
| BEP Sex(F)         | CTRL  | 20.54 |       |                |         |  |
|                    | TRT   | 22.85 | 2.3   | (-0.07 - 4.67) | 0.057   | -  |
| ITT Sex(M)         | CTRL  | 19.57 |       |                |         |  |
|                    | TRT   | 22.24 | 2.67  | (0.82 – 4.51)  | 0.0048  |  |
| BEP Sex(M)         | CTRL  | 18.93 |       |                |         |  |
|                    | TRT   | 21.99 | 3.06  | (0.64 – 5.48)  | 0.013   |  |
| ITT Age(>=50%, 53) | CTRL  | 19.1  |       |                |         |  |
|                    | TRT   | 22.05 | 2.95  | (1.07 – 4.83)  | 0.0022  |  |
| BEP Age(>=50%, 53) | CTRL  | 18.82 |       |                |         |  |
|                    | TRT   | 22.68 | 3.85  | (1.44 – 6.27)  | 0.0019  |  |
| ITT Age(<50%, 53)  | CTRL  | 19.32 |       |                |         |  |
|                    | TRT   | 22.33 | 3.01  | (1.14 – 4.87)  | 0.0017  |  |
| BEP Age(<50%, 53)  | CTRL  | 20.38 |       |                |         |  |
|                    | TRT   | 22.1  | 1.72  | (-0.68 - 4.12) |         |  |
|                    |       |       |       |                |         | 0 1 2 3 4 5 6<br>< TRT better [ delta ] CTRL better> |

# **Full population**

## N=89 N=93 40 30 20 10 0 **CTRL TRT CTRL TRT** Arm| F M Sex

## BEP





#### ## [1] ""

Mutant (29.14%)

Wild Typ.. (70.86%)

## 3 Biomarker property and its association to clinical variables

Relationship between the biomarker and key demographic and prognostic variables should also be investigated using bivariate plots. Prognostic property of the biomarker should also be assessed, by estimates of the clinical efficacy in the control arm.

#### 3.1 Biomarker property and relationship to clinical variable

The following results show single variate plot for biomaker and bi-variate plots to investigate biomarker-clinical variable relationship.

```
PlotProperty(data=input, biomarker.var=bm, biomarker.class=bm.class,
                var=clinical.vars,
                var.class=clinical.vars.class,
                log2=FALSE, par.param = list(mfrow=c(2,3)))
         Distribution of KRAS.mutant
                                              Distribution of KRAS.mutant by Sex
                                                                                          Age by KRAS.mutant
                                                                               90
                                                                               80
                                       100
                                                                               20
150
                                                                               9
100
                                                                               20
50
                                        20
```

M (47.37%)

Mutant

Wild Typ..


F (52.63%)

#### 3.2 Whether the biomarker shows within-arm effect

The following figures investigate whether the biomarker shows a within-arm effect (e.g. patients in one biomarker subgroup tend to have better clinical outcome):

```
## Stratification is not supported for continuous outcome
## Some NAs in var column, will define the non NA entries as BEP
## only 1 arm; show.itt is set to FALSE
## only 1 arm; show.bep is set to FALSE
```

#### CTRL Within-arm Effect of Biomarker Lab\_ontrt, KRAS.mutant Unadjusted, unstratified analysis



```
## Stratification is not supported for continuous outcome

## Some NAs in var column, will define the non NA entries as BEP

## only 1 arm; show.itt is set to FALSE


## only 1 arm; show.bep is set to FALSE

## Warning in par(old.par): calling par(new=TRUE) with no plot

TRT Within-arm Effect of Biomarker

Lab_ontrt, KRAS.mutant

Unadjusted, unstratified analysis
```



The forest plots above show within-arm mean difference (delta) across biomarker subgroups. For a given arm, if the delta is not all around 0, it indicates that within this arm the biomarker has an association to the clinical outcome.

If similar trend is seen in both arms, it indicates that the biomarker may have a prognostic effect (the biomarker is able to identify patients with better/worse clinical outcome, regardless of treatment).

## 4 Biomarker subgroup analysis

#### 4.1 Estimations within each subgroup


The following figure shows estimate of treatment effect in biomarker subgroups.

```
if(bm.class=="numeric"){
if(!is.null(numerical.finalcut)) levs <- pasteO(c(">=","<"),numerical.finalcut)
if(is.null(numerical.finalcut)) {
   nm <- quantile(input.bep[[bm]],percentile.finalcut, 2) # default quantile type in forest plot s
   numerical.finalcut <- round(nm,2) # default rounding decimal in forest plots
   levs <- pasteO(c(">=","<"),percentile.finalcut*100,"%")
}
bm2 <- pasteO(bm,"_Dx")
input[[bm2]] <- ifelse(input[[bm]] >= numerical.finalcut, levs[1],levs[2])
input[[bm2]] <- factor(input[[bm2]], levels=levs) # ">=" as Dx+
}
```

## Stratification is not supported for continuous outcome

## Some NAs in var column, will define the non NA entries as BEP


#### Across-arm Effect of Biomarker Lab\_ontrt, KRAS.mutant Unadjusted, unstratified analysis



#### 4.2 Subgroup analysis

The following figure show distribution of the continuous endpoint within the biomarker subgroups:

**BEP:** biomarker subgroups



# 4.3 Check whether biomarker subgroup is confounded with key clinical variables

The following table checks whether the biomarker subgroup is confounded with clinical variables. Here we check whether the clinical variable distribution is comparable in biomarker subgroups.

```
kable(
SummaryVars(data=input.bep,trt=trt, subgroup=bm2, var=clinical.vars,
var.class=clinical.vars.class, subgroup.indicator=levs[i],compare.subgroup=TRUE)
)
```

|         | $KRAS.mutant\_Mutant(CTRL)$ | $KRAS.mutant\_Wild\ Type(CTRL)$ | $KRAS.mutant\_Mutant(TRT)$ | $KRAS.mutant\_Wild\ Type(TRT)$ |
|---------|-----------------------------|---------------------------------|----------------------------|--------------------------------|
| Sex     |                             |                                 |                            |                                |
| Total   | 34                          | 69                              | 61                         | 162                            |
| NA's    | 0                           | 0                               | 0                          | 0                              |
| F       | 15 (44.12%)                 | 32 (46.38%)                     | 35 (57.38%)                | 76 (46.91%)                    |
| M       | 19 (55.88%)                 | 37 (53.62%)                     | 26 (42.62%)                | 86 (53.09%)                    |
| Age     | ,                           | · · · ·                         | , ,                        | · · · · ·                      |
| N       | 34                          | 69                              | 61                         | 162                            |
| Mean    | 51.88                       | 53.45                           | 54.92                      | 54.03                          |
| Median  | 52                          | 52                              | 54                         | 53                             |
| Min-Max | 3677                        | 3285                            | 3489                       | 3382                           |
| NA's    | 0                           | 0                               | 0                          | 0                              |